These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

650 related items for PubMed ID: 25066602

  • 21. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.edu.
    Ballantyne CM, Davidson MH, Setze CM, Kelly MT.
    J Clin Lipidol; 2011; 5(5):401-7. PubMed ID: 21981842
    [Abstract] [Full Text] [Related]

  • 22. [Non-ST-elevation acute coronary syndrome. Comparison of effects of atorvastatin and rosuvastatin on blood levels of lipids and markers of inflammation].
    Kuznetsova MA, Vaulin NA, Masenko VP, Gratsianskiĭ NA.
    Kardiologiia; 2010; 50(2):21-5. PubMed ID: 20146674
    [Abstract] [Full Text] [Related]

  • 23. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
    Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE.
    JAMA; 2011 Nov 16; 306(19):2099-109. PubMed ID: 22089718
    [Abstract] [Full Text] [Related]

  • 24. [Treatment for dyslipidemias in patients with arterial hypertension].
    Chazova IE, Kukharchuk VV, Ratova LG, Kaminnaia VI.
    Ter Arkh; 2007 Nov 16; 79(4):53-7. PubMed ID: 17564020
    [Abstract] [Full Text] [Related]

  • 25. Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe.
    Yamazaki D, Ishida M, Watanabe H, Nobori K, Oguma Y, Terata Y, Koyama T, Iino K, Kosaka T, Ito H.
    Lipids Health Dis; 2013 Feb 04; 12():9. PubMed ID: 23374898
    [Abstract] [Full Text] [Related]

  • 26. Rosuvastatin improves plaque morphology in cerebral embolism patients with normal low-density lipoprotein and severe aortic arch plaque.
    Kaneko K, Saito H, Takahashi T, Kiribayashi N, Omi K, Sasaki T, Niizeki T, Sugawara S, Akasaka M, Kubota I.
    J Stroke Cerebrovasc Dis; 2014 Jul 04; 23(6):1682-9. PubMed ID: 24739590
    [Abstract] [Full Text] [Related]

  • 27. Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study.
    Rosenson RS, Otvos JD, Hsia J.
    Diabetes Care; 2009 Jun 04; 32(6):1087-91. PubMed ID: 19265025
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
    Roth EM, Rosenson RS, Carlson DM, Fukumoto SM, Setze CM, Blasetto JW, Khurmi NS, Stolzenbach JC, Williams LA.
    Cardiovasc Drugs Ther; 2010 Dec 04; 24(5-6):421-8. PubMed ID: 20953684
    [Abstract] [Full Text] [Related]

  • 29. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
    McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group.
    Circulation; 2009 Dec 01; 120(22):2188-96. PubMed ID: 19917888
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
    Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.
    Atherosclerosis; 2009 May 01; 204(1):208-15. PubMed ID: 18996523
    [Abstract] [Full Text] [Related]

  • 31. Rosuvastatin-Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study.
    Rollefstad S, Ikdahl E, Hisdal J, Olsen IC, Holme I, Hammer HB, Smerud KT, Kitas GD, Pedersen TR, Kvien TK, Semb AG.
    Arthritis Rheumatol; 2015 Jul 01; 67(7):1718-28. PubMed ID: 25778850
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Rosuvastatin--a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients.
    Schuster H.
    Cardiology; 2003 Jul 01; 99(3):126-39. PubMed ID: 12824720
    [Abstract] [Full Text] [Related]

  • 34. Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia.
    Capuzzi DM, Morgan JM, Carey CM, Intenzo C, Tulenko T, Kearney D, Walker K, Cressman MD.
    Prev Cardiol; 2004 Jul 01; 7(4):176-81. PubMed ID: 15539964
    [Abstract] [Full Text] [Related]

  • 35. Combining rosuvastatin with angiotensin-receptor blockers of different PPARγ-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes.
    Rizos CV, Liberopoulos EN, Tellis K, DiNicolantonio JJ, Tselepis AD, Elisaf MS.
    Angiology; 2015 Jan 01; 66(1):36-42. PubMed ID: 24288364
    [Abstract] [Full Text] [Related]

  • 36. Lipid-lowering efficacy of rosuvastatin.
    Adams SP, Sekhon SS, Wright JM.
    Cochrane Database Syst Rev; 2014 Nov 21; 2014(11):CD010254. PubMed ID: 25415541
    [Abstract] [Full Text] [Related]

  • 37. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome.
    Ballantyne CM, Stein EA, Paoletti R, Southworth H, Blasetto JW.
    Am J Cardiol; 2003 Mar 06; 91(5A):25C-27C; discussion 28C. PubMed ID: 12646342
    [Abstract] [Full Text] [Related]

  • 38. Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction.
    Aydin MU, Aygul N, Altunkeser BB, Unlu A, Taner A.
    Atherosclerosis; 2015 Apr 06; 239(2):439-43. PubMed ID: 25697576
    [Abstract] [Full Text] [Related]

  • 39. Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies.
    Pepine CJ, Jacobson TA, Carlson DM, Kelly MT, Setze CM, Gold A, Stolzenbach JC, Williams LA.
    Clin Cardiol; 2010 Oct 06; 33(10):609-619. PubMed ID: 20960535
    [Abstract] [Full Text] [Related]

  • 40. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk.
    Calza L, Manfredi R, Colangeli V, Trapani FF, Salvadori C, Magistrelli E, Danese I, Verucchi G, Serra C, Viale P.
    AIDS Res Hum Retroviruses; 2013 Mar 06; 29(3):547-56. PubMed ID: 23098891
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.